Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3753)	10/8/1999 11:57:00 PM
From: Vector1	Read Replies (2) \| Respond to of 10280

Peter, One of the key drivers of SEPR over the next 6 months will be the results of Xopenex trial. I found the following from a recent analyst report quite interesting: ----------------------------------------------------- Is there any upside in Xopenex? While our expectations for Xopenex are reduced, we feel it is important to note that the company is engaged in the Troff study that is evaluating the longer-term effects of the S-isomer, which has been removed from racemic albuterol to generate Xopenex. The study is based on findings from the Phase III trials that indicated lung function improvement compared to placebo and baseline when patients took Xopenex. This contrasts with data that suggests lung function may be somewhat compromised when taking racemic albuterol for the same period of time. Sepracor is engaged in a Phase III trial exploring this potential phenomenon. The data should be available in the fourth quarter, and could provide some power to the Xopenex campaign if a significant relationship is detailed.